- Article
- Published:
Exome sequencing to identifyde novo mutations in sporadic ALS trios
- Alessandra Chesi1,
- Brett T Staahl2,
- Ana Jovičić1,
- Julien Couthouis1,
- Maria Fasolino3,
- Alya R Raphael1,
- Tomohiro Yamazaki4,
- Laura Elias2,
- Meraida Polak5,
- Crystal Kelly5,
- Kelly L Williams6,7,8,
- Jennifer A Fifita6,8,
- Nicholas J Maragakis9,
- Garth A Nicholson6,7,
- Oliver D King10,
- Robin Reed4,
- Gerald R Crabtree2,
- Ian P Blair6,7,8,
- Jonathan D Glass5 &
- …
- Aaron D Gitler1
Nature Neurosciencevolume 16, pages851–855 (2013)Cite this article
11kAccesses
137Citations
51Altmetric
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease whose causes are still poorly understood. To identify additional genetic risk factors, we assessed the role ofde novo mutations in ALS by sequencing the exomes of 47 ALS patients and both of their unaffected parents (n = 141 exomes). We found that amino acid–alteringde novo mutations were enriched in genes encoding chromatin regulators, including the neuronal chromatin remodeling complex (nBAF) componentSS18L1 (also known asCREST). CREST mutations inhibited activity-dependent neurite outgrowth in primary neurons, and CREST associated with the ALS protein FUS. These findings expand our understanding of the ALS genetic landscape and provide a resource for future studies into the pathogenic mechanisms contributing to sporadic ALS.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
￥ 4,980
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andersen, P.M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know?Nat. Rev. Neurol.7, 603–615 (2011).
Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.Science319, 1668–1672 (2008).
Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.Science323, 1208–1211 (2009).
Kwiatkowski, T.J. et al. Mutations in theFUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.Science323, 1205–1208 (2009).
Johnson, J.O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS.Neuron68, 857–864 (2010).
Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis.Nature465, 223–226 (2010).
Deng, H.X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.Nature477, 211–215 (2011).
Wu, C.H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.Nature488, 499–503 (2012).
DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.Neuron72, 245–256 (2011).
Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.Neuron72, 257–268 (2011).
Rosen, D.R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.Nature362, 59–62 (1993).
O'Roak, B.J. et al. Sporadic autism exomes reveal a highly interconnected protein network ofde novo mutations.Nature485, 246–250 (2012).
Neale, B.M. et al. Patterns and rates of exonicde novo mutations in autism spectrum disorders.Nature485, 242–245 (2012).
Sanders, S.J. et al.De novo mutations revealed by whole-exome sequencing are strongly associated with autism.Nature485, 237–241 (2012).
Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum.Neuron74, 285–299 (2012).
Xu, B. et al. Exome sequencing supports ade novo mutational paradigm for schizophrenia.Nat. Genet.43, 864–868 (2011).
Girard, S.L. et al. Increased exonicde novo mutation rate in individuals with schizophrenia.Nat. Genet.43, 860–863 (2011).
Vissers, L.E. et al. Ade novo paradigm for mental retardation.Nat. Genet.42, 1109–1112 (2010).
Alexander, M.D. et al. “True” sporadic ALS associated with a novel SOD-1 mutation.Ann. Neurol.52, 680–683 (2002).
Chiò, A. et al. Ade novo missense mutation of the FUS gene in a “true” sporadic ALS case.Neurobiol. Aging32, e23–e26 (2011).
DeJesus-Hernandez, M. et al.De novo truncatingFUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis.Hum. Mutat.31, E1377–E1389 (2010).
Huang, D.W. et al. Extracting biological meaning from large gene lists with DAVID.Curr. Protoc. BioinformaticsChapter 13, 13.11 (2009).
Ryu, H. et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.J. Neurochem.93, 1087–1098 (2005).
Rouaux, C. et al. Sodium valproate exerts neuroprotective effectsin vivo through CREB-binding protein–dependent mechanisms, but does not improve survival in an amyotrophic lateral sclerosis mouse model.J. Neurosci.27, 5535–5545 (2007).
Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells.Sci. Transl. Med.4, 145ra104 (2012).
Cudkowicz, M.E. et al. Phase 2 study of sodium phenylbutyrate in ALS.Amyotroph. Lateral Scler.10, 99–106 (2009).
Gil, O.D., Zanazzi, G., Struyk, A.F. & Salzer, J.L. Neurotrimin mediates bifunctional effects on neurite outgrowth via homophilic and heterophilic interactions.J. Neurosci.18, 9312–9325 (1998).
van Horck, F.P., Lavazais, E., Eickholt, B.J., Moolenaar, W.H. & Divecha, N. Essential role of type I(alpha) phosphatidylinositol 4-phosphate 5-kinase in neurite remodeling.Curr. Biol.12, 241–245 (2002).
Aizawa, H. et al. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.Science303, 197–202 (2004).
Qiu, Z. & Ghosh, A. A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression.Neuron60, 775–787 (2008).
Wu, J.I. et al. Regulation of dendritic development by neuron-specific chromatin remodeling complexes.Neuron56, 94–108 (2007).
Kabashi, E. et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficitsin vivo.Hum. Mol. Genet.19, 671–683 (2010).
Khavari, P.A., Peterson, C.L., Tamkun, J.W., Mendel, D.B. & Crabtree, G.R. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription.Nature366, 170–174 (1993).
Fujii, R. et al. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology.Curr. Biol.15, 587–593 (2005).
Cushman, M., Johnson, B.S., King, O.D., Gitler, A.D. & Shorter, J. Prion-like disorders: blurring the divide between transmissibility and infectivity.J. Cell Sci.123, 1191–1201 (2010).
Gitler, A.D. & Shorter, J. RNA-binding proteins with prion-like domains in ALS and FTLD-U.Prion5, 179–187 (2011).
King, O.D., Gitler, A.D. & Shorter, J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.Brain Res.1462, 61–80 (2012).
Couthouis, J. et al. A yeast functional screen predicts new candidate ALS disease genes.Proc. Natl. Acad. Sci. USA108, 20881–20890 (2011).
Couthouis, J. et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis.Hum. Mol. Genet.21, 2899–2911 (2012).
Kim, H.J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.Nature495, 467–473 (2013).
Monroy, M.A. et al. Regulation of cAMP-responsive element–binding protein–mediated transcription by the SNF2/SWI-related protein, SRCAP.J. Biol. Chem.276, 40721–40726 (2001).
Wang, X. et al. Induced ncRNAs allosterically modify RNA-binding proteins incis to inhibit transcription.Nature454, 126–130 (2008).
Bultman, S. et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes.Mol. Cell6, 1287–1295 (2000).
Tsurusaki, Y. et al. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.Nat. Genet.44, 376–378 (2012).
Wolff, D. et al. In-frame deletion and missense mutations of the C-terminal helicase domain of SMARCA2 in three patients with Nicolaides-Baraitser syndrome.Mol. Syndromol.2, 237–244 (2012).
Van Houdt, J.K. et al. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome.Nat. Genet.44, 445–449 (2012).
Hoyer, J. et al. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability.Am. J. Hum. Genet.90, 565–572 (2012).
Loe-Mie, Y. et al. SMARCA2 and other genome-wide supported schizophrenia-associated genes: regulation by REST/NRSF, network organization and primate-specific evolution.Hum. Mol. Genet.19, 2841–2857 (2010).
Lule, D., Ludolph, A.C. & Ludolph, A.G. Neurodevelopmental and neurodegenerative diseases: is there a pathophysiological link? Attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis as examples.Med. Hypotheses70, 1133–1138 (2008).
Calvo, A.C. et al. Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice.PLoS ONE7, e32632 (2012).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.Bioinformatics25, 1754–1760 (2009).
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.Genome Res.20, 1297–1303 (2010).
DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data.Nat. Genet.43, 491–498 (2011).
Hosack, D.A., Dennis, G. Jr., Sherman, B.T., Lane, H.C. & Lempicki, R.A. Identifying biological themes within lists of genes with EASE.Genome Biol.4, R70 (2003).
Dufu, K. et al. ATP is required for interactions between UAP56 and two conserved mRNA export proteins, Aly and CIP29, to assemble the TREX complex.Genes Dev.24, 2043–2053 (2010).
Folco, E.G., Lei, H., Hsu, J.L. & Reed, R. Small-scale nuclear extracts for functional assays of gene-expression machineries.J. Vis. Exp.64, e4140 (2012).
Acknowledgements
This work was supported by a US National Institutes of Health Director's New Innovator Award 1DP2OD004417 (A.D.G.), grants from the US National Institutes of Health (1R01NS065317 to A.D.G., R01NS046789 to G.R.C. and 5U01NS062713 to N.J.M.) and the Department of Defense ALS Research Program (N.J.M.). A.D.G. received funding from the Biogen Idec ALS genome sequencing consortium. A.D.G. received funding from The Pew Charitable Trusts and the Rita Allen Foundation. G.R.C. receives funding from the Howard Hughes Medical Institute. A.D.G. and J.D.G. are supported by the Packard Center for ALS Research at Johns Hopkins. This work was also supported by the National Health and Medical Research Council of Australia (1004670, 511941) and the Motor Neurone Disease Research Institute of Australia.
Author information
Authors and Affiliations
Department of Genetics, Stanford University School of Medicine, Stanford, California, USA
Alessandra Chesi, Ana Jovičić, Julien Couthouis, Alya R Raphael & Aaron D Gitler
Howard Hughes Medical Institute and Department of Developmental Biology, Stanford University School of Medicine, Stanford, California, USA
Brett T Staahl, Laura Elias & Gerald R Crabtree
Neuroscience Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Maria Fasolino
Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA
Tomohiro Yamazaki & Robin Reed
Department of Neurology, Emory University, Atlanta, Georgia, USA
Meraida Polak, Crystal Kelly & Jonathan D Glass
Northcott Neuroscience Laboratory, Australian and New Zealand Army Corps Research Institute, Sydney, Australia
Kelly L Williams, Jennifer A Fifita, Garth A Nicholson & Ian P Blair
Sydney Medical School, University of Sydney, Sydney, Australia
Kelly L Williams, Garth A Nicholson & Ian P Blair
Australian School of Advanced Medicine, Macquarie University, Sydney, Australia
Kelly L Williams, Jennifer A Fifita & Ian P Blair
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Nicholas J Maragakis
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Oliver D King
- Alessandra Chesi
Search author on:PubMed Google Scholar
- Brett T Staahl
Search author on:PubMed Google Scholar
- Ana Jovičić
Search author on:PubMed Google Scholar
- Julien Couthouis
Search author on:PubMed Google Scholar
- Maria Fasolino
Search author on:PubMed Google Scholar
- Alya R Raphael
Search author on:PubMed Google Scholar
- Tomohiro Yamazaki
Search author on:PubMed Google Scholar
- Laura Elias
Search author on:PubMed Google Scholar
- Meraida Polak
Search author on:PubMed Google Scholar
- Crystal Kelly
Search author on:PubMed Google Scholar
- Kelly L Williams
Search author on:PubMed Google Scholar
- Jennifer A Fifita
Search author on:PubMed Google Scholar
- Nicholas J Maragakis
Search author on:PubMed Google Scholar
- Garth A Nicholson
Search author on:PubMed Google Scholar
- Oliver D King
Search author on:PubMed Google Scholar
- Robin Reed
Search author on:PubMed Google Scholar
- Gerald R Crabtree
Search author on:PubMed Google Scholar
- Ian P Blair
Search author on:PubMed Google Scholar
- Jonathan D Glass
Search author on:PubMed Google Scholar
- Aaron D Gitler
Search author on:PubMed Google Scholar
Contributions
A.C. performed all of the exome sequencing and analysis. B.T.S. and A.J. performed the primary neuron experiments. B.T.S. performed co-immunoprecipitation experiments with direction from G.R.C. J.C., M.F. and A.R.R. performed Sanger sequencing and helped A.C. with exome sequencing. T.Y. and R.R. performed SS18L1-FUS physical association experiments. L.E. performed mass spectrometry analysis. N.J.M. and J.D.G. contributed ALS patient samples, with assistance from M.P. and C.K., and helped to design experiments. K.L.W., J.A.F., G.A.N. and I.P.B. contributed ALS patient samples and performed experiments to identifySS18L1 variants in Australian FALS pedigrees. O.D.K. performed prion-like domain analysis for SS18L1 and SS18. A.D.G. and A.C. wrote the manuscript with input from all of the authors.
Corresponding authors
Correspondence toAlessandra Chesi orAaron D Gitler.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 and Supplementary Tables 1–3 (PDF 1083 kb)
Rights and permissions
About this article
Cite this article
Chesi, A., Staahl, B., Jovičić, A.et al. Exome sequencing to identifyde novo mutations in sporadic ALS trios.Nat Neurosci16, 851–855 (2013). https://doi.org/10.1038/nn.3412
Received:
Accepted:
Published:
Issue date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
Modelling amyotrophic lateral sclerosis in rodents
- Tiffany W. Todd
- Leonard Petrucelli
Nature Reviews Neuroscience (2022)
A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics
- Gaël Nicolas
- Myriam Sévigny
- Chantelle F. Sephton
Acta Neuropathologica Communications (2022)
Protein expression pattern of calcium-responsive transactivator in early postnatal and adult testes
- Ana Du
- Li Li
- He Li
Histochemistry and Cell Biology (2021)
CRISPR-mediated gene correction links the ATP7A M1311V mutations with amyotrophic lateral sclerosis pathogenesis in one individual
- Yeomin Yun
- Sung-Ah Hong
- Yoon Ha
Communications Biology (2020)
Loss of CREST leads to neuroinflammatory responses and ALS-like motor defects in mice
- Cheng Cheng
- Kan Yang
- Zilong Qiu
Translational Neurodegeneration (2019)
